Plasma ghrelin is probably not a useful biomarker for risk prediction or early detection of colorectal cancer
| Autor: | Sophia Harlid, Anneli Sundkvist, Richard Palmqvist, Bethany Van Guelpen, Robin Myte |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
gastrointestinal hormones 0301 basic medicine Oncology medicine.medical_specialty Colorectal cancer Early detection colorectal cancer Adenocarcinoma Sensitivity and Specificity Article 03 medical and health sciences 0302 clinical medicine Predictive Value of Tests Risk Factors Internal medicine medicine Biomarkers Tumor cancer Humans Finland Early Detection of Cancer Aged business.industry Smoking digestive oral and skin physiology Gastroenterology Cancer Public Health Global Health Social Medicine and Epidemiology PostScript Middle Aged medicine.disease Ghrelin Folkhälsovetenskap global hälsa socialmedicin och epidemiologi 030104 developmental biology Case-Control Studies Biomarker (medicine) epidemiology 030211 gastroenterology & hepatology business Colorectal Neoplasms hormones hormone substitutes and hormone antagonists |
| Zdroj: | Gut |
| ISSN: | 1468-3288 |
| Popis: | Colorectal cancers are the third most common cancers in women and men in the USA. While dietary and lifestyle factors such as Western diet, physical inactivity and obesity have been linked to an increased risk of this malignancy, the mechanisms for these associations are unclear. GI hormones, including ghrelin, are involved in energy balance by mediating appetite and metabolism; however, the association between ghrelin and colorectal cancer has not been studied.We conducted a case-control study nested within the all-male Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of Finnish smokers (aged 50-69 years) to examine serum ghrelin concentration and colorectal cancer risk. Data from 284 colon and 239 rectal cancers and 523 controls (matched on age, date of blood draw and serum availability) were analysed. ORs and 95% CIs were calculated using multivariable (conditional) logistic regression.Overall, low-serum ghrelin was significantly associated with increased risk of colorectal cancer (Q1 vs Q4: OR:1.57, 95% CI 1.05 to 2.34). For individuals developing tumours within 10 years of blood draw, those in the lowest quartile of serum ghrelin concentrations were statistically significantly more likely to develop colorectal cancers than those with higher serum ghrelin concentrations (OR: 10.86, 95% CI 5.01 to 23.55). However, for individuals with tumours developing more than 20 years after blood draw, low-serum ghrelin concentrations were associated with a decreased risk of colorectal cancer relative to those with the highest serum ghrelin concentrations (OR: 0.26, 95% CI 0.11 to 0.64).Low-serum ghrelin was associated with an increased colorectal cancer risk within 10 years of blood draw with a decreased risk for developing colorectal cancer more than 20 years after blood draw. These results suggest that ghrelin concentrations may vary across the carcinogenic process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|